newsfilter
← Latest News
GlobeNewswire·

Morphic Announces Complete Enrollment of EMERALD-1 Main Cohort Ahead of Projections

WALTHAM, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases,